Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Nexalin Technology Q3 2026 Results: Net Loss of $2.66M, Loss Widens

Nexalin Technology reported a net loss of $6,998,075 for the nine months ended September 30, 2026, compared to $5,845,635 in the prior year period. While revenues for the third quarter increased year-over-year to $78,301, the company continues to face significant operating expenses and an accumulated deficit of nearly $100 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.10.0
Gross profit0.10.0
Profit before tax-2.7-2.3
Net income-2.7-2.3
EPS (diluted, $ a share)$-3.43$-3.84

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+331.4%
Gross margin71.1%
Source

10-Q filed with the SEC, NASDAQ: NXL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Nexalin Technology, Inc.: key numbers

Share price
$1.56Close, Nov 16
Market cap
$1.93M
Shares outstanding
1.24MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Electromedical & Electrotherapeutic ApparatusSIC 3845

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Nexalin Technology, Inc.

All →
5:00 PM ET 8-K
Partnership

Nexalin Technology Partnership with Inovanexa Medical Technologies S.A.

Nexalin Technology entered into a definitive exclusive distribution agreement with Inovanexa Medical Technologies S.A. (operating as Nexalin LATAM) to commercialize the Nexalin Sync™ neurostimulation device across seven South American countries. The 10-year agreement includes an initial 100-device program, minimum revenue thresholds to maintain exclusivity, and a requirement for the distributor to fund and establish a local manufacturing facility in Brazil after the first 30 devices are purchased.

Counterparty
Inovanexa Medical Technologies S.A.
Term
10 years
5:00 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Nexalin Technology Nasdaq/NYSE Compliance Notice

Nexalin Technology has regained compliance with Nasdaq's $1.00 minimum bid price requirement. However, the company remains under a compliance plan to meet the $2.5 million minimum stockholders' equity requirement by January 4, 2027. Failure to meet this remaining equity threshold will subject the company's common stock to delisting.

Counterparty
The Nasdaq Stock Market LLC
5:16 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Nexalin Technology Nasdaq/NYSE Compliance Notice

Nexalin Technology received a notification from the Nasdaq Hearings Panel granting a conditional extension to regain compliance with listing standards. The company must demonstrate a minimum bid price of $1.00 for 20 consecutive trading sessions by September 28, 2026, and meet the $2.5 million stockholders' equity requirement by January 4, 2027.

Counterparty
Nasdaq

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.